BGNE vs. BMRN, VTRS, SRPT, ALNY, UTHR, RDY, TEVA, GMAB, CTLT, and ROIV
Should you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical (NASDAQ:BMRN) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
BioMarin Pharmaceutical has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 48.6% of BeiGene shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 7.4% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, BioMarin Pharmaceutical had 24 more articles in the media than BeiGene. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 10 mentions for BeiGene. BioMarin Pharmaceutical's average media sentiment score of 0.92 beat BeiGene's score of 0.24 indicating that BeiGene is being referred to more favorably in the news media.
BioMarin Pharmaceutical received 995 more outperform votes than BeiGene when rated by MarketBeat users. Likewise, 74.70% of users gave BioMarin Pharmaceutical an outperform vote while only 69.14% of users gave BeiGene an outperform vote.
BioMarin Pharmaceutical presently has a consensus price target of $106.11, indicating a potential upside of 36.80%. BeiGene has a consensus price target of $251.93, indicating a potential upside of 45.75%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BeiGene is more favorable than BioMarin Pharmaceutical.
BioMarin Pharmaceutical has a net margin of 8.31% compared to BioMarin Pharmaceutical's net margin of -28.39%. BeiGene's return on equity of 5.34% beat BioMarin Pharmaceutical's return on equity.
BioMarin Pharmaceutical has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Summary
BioMarin Pharmaceutical beats BeiGene on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
